Spindle ce ll lipom as are usually locat ed in the sub cutan eous tissue of the back, sho ulde rs, and neck. To our knowledge, the presence of such a tum or in the parapharyngeal spac e ha s not ye t been descr ibed. We evaluated a 45 -yea r-old man with a tender swe lling of the right parotid area that had rea ched the submandibula r area. Clin ical examination and ma gn eti c resonan ce imagin g reveal ed th e presence of a tum or that coated the parotid area lat erally and extended into the center ofthe parapharyngea l spa ce, thus causing a dis location of the pharyngeal mu scles and mu cosa. We p erformed a tota l parotidectom y and submandibulectom y on the righ t side and ext irpa ted the paraph aryngeal tumo r. We were ab le to spare the facia l nerve , and no facia l paralysis occurred. Histologic examination revealed an atyp ica l lipo matous tumor with a rema rkably large po rtion of spindles. A 45 -year-old man wa s eva luated in May 1998 for a ten der swe lling in his right paro tid area. He said that he had also experienced an ipsilateral hearin g im pai rment for the pre vio us 10 weeks. He reported no pain , difficultie s in swallowing, or other complai nts.
Introduction
Sp indle ce ll lipom a was first described by Enzi nger and Harvey in 1975 as a variant of the typical benign lipoma. I Its histologic pattern fea tures matu re, univacuolar fat ce lls and fibro blast-like spindle cells in a matrix of co llagen and mucoi d ma ter ial. T he tumor is localized predo minantly in the subcutaneous tissue of the back, shoulders, and neck.' To our kno wledge, no other case of a lipomatous tumor arising in the parapharyngeal space has thus far been described .
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Cevimeline inten sity and con siderabl e co ntras t enhance me nt. Th e maximum di mensions of the entire tumor were 75 x 30 x 60 mm, and the margins were we ll defined. Th e tu mor had displaced but not infiltrated the adjace nt muscle s and mucou s structures. No other sec tions of the head or neck were invo lved.
We per form ed a total parotidectomy and subman dibulectom y and extirpated the paraph aryngeal tum or on the right side . Th e facial ner ve was retained intact.
Histologicall y, we found a co nspicuous ly heterogeneou s tum or that was marked by a predom inance of matu re, uni vacu olar fat cells and dissemin ated foc i of spindle-s hape d fibro blast -like ce lls (figure 3). A few sca ttered tumor cells contai ned bizarre-looking and partially hyperch rom atic nuclei. Lip oblasts were virtuall y abse nt. A few mitoses co uld be detec ted . Th e tumor matrix appeared to be partl y fibro us and par tly mu coid. Th e pathologic-anatomi c diag nosis was a typical lipom atou s tum or with a prom inent spindle cell co mpo nent.
Th e surgical wound healed without co mplication, and all nerve functio ns rem ained int act. During the first few days postoper atively, there was an incom plete facial nerve pa lsy of the marginal ramus, but it disappeared rap idly afte r phy siot herapy .
Discussion
Approxi mate ly 15% of all lipo mato us tumors occ ur in the head and neck.' According to Fiigema nn, the beni gn lipom atou s tum ors of this reg ion ca n be further subclassified as so litary or mult iple cl assic lipomas; infiltrat ing or intra muscu lar lipomas; hib ern omas; lipoblastomas (socalled fetal lipom as); and diffuse lipom as in childre n.' Th e classic encapsulated lipo mas are among the mo st common mesenchymal tumors.
Mos t lipom as are localized in the su bcuta neous tissue of the back, shoulders, and neck. In rare cases , they affec t the ora l cav ity,' tonsillar area ," parotid area, ' hypopharynx, " lary nx,"!' and nasopharynx. '? Li po mas of the paraph aryn geal space are very rare; only five cases have been describ ed ,13·1 7 Chond rolip om as18 and osteolipornas" of the para pharyngeal space are extre me ly rare.
Th e spindle ce ll lipom a is a varian t of the classic lipo ma, and it can easily be mistaken for a liposarcoma. Enzinger and Ha rvey first described this relatively unusual lipomatous tumor in 1975. 1 Only 1.5% of alllipomas are spindle ce ll lipomas.20 In 75% of all cases , sp indle cell lipom as are localized in the area s of the back, sho ulders, and neck." This tum or has a pa rtic ularly high freque ncy in men between the ages of 40 and 70 yea rs. Spindle cell lipom as in the mucoid tiss ues of the head and neck are very rare; they have been described in the ora l cavity,' :":" pa latine tonsil," and laryn x."
To the best of our know ledge, no ca se of a spindle ce ll lipoma of the parapharyngeal space has thus far been described . Fletcher and Martin -Bates analyzed data obtained on lipo mato us tumo rs at St. T ho mas' s Hospital Medical Sc hoo l in London fro m 1961 to 1986. 20 They discovered 4 1 cases of spindle cell lipom a in a total of 2,478 lipom atou s tumors, and none of them had been locali zed in the par aph aryngeal space, BAUMANN, DAMMANN, HORNY , PLiNKERT c D Histo logically, lipom as co nsis t of a lobular proliferation of mature, univacuolar fat ce lls in a fibro us co nnective tissue stroma. Terms such as fib rolipoma, bemangiolipoina, and myxolipoma are used when additional histologic components are apparent. Spindle cell lipomas and fibro lipomas are morphologically similar beca use both have a stro ma rich in collagen fibri ls. They can be distinguished from each other by the presence or absenc e of spindle-like fibro blas tsY .
It is of major importance that spindle cell lipomas can be mistaken for liposarcomas both clinica lly and histologicall y. Spindle cell lipom as are characterized by bund les of relativ ely uniform spindle cell s, bro ad coll agen fibril s, and the absence of lipoblasts, which are a main diagno stic featur e of liposarcomas.?" Plexiform," nodu lar," and pseud oangiomatous-":" var iant s of spindle cell lipomas have been described.
As multip le lipomas, multiple spindle cell lipomas ofte n occur among re lated individua ls. Fanb urg -Smi th et al reported on four patients in a si ngle fami ly who were found to have multiple spin dle ce ll lipomas and three 248 ad ditio nal patie nts w ith a co mpa rable fami ly history."
T he treat ment of choice for spindle ce ll lipo ma is a complete local excision. Recurrences are very rare , but the possibi lity cannot be di smissed . Enzinger and Harvey' found no rec urrences in 63 operated spindle cell lipomas, and Fletcher and Martin-Bate s'? found only one recurrence in 41 tumors.
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